VC Atlas takes on biotech veteran Kevin Bitterman

Bitterman has worked at Polaris and been involved in founding a number of high spec biotechs.

Atlas Venture has made biotech veteran Kevin Bitterman a new partner, joining the firm’s team from Polaris.

Bitterman brings a wealth of experience to the role, having been the founding CEO of CRISPR biotech Editas Medicine, Morphic Therapeutic and Visterra, as well as co-founder of Genocea Biosciences.

“I couldn’t be more thrilled to join Atlas at such an exciting time for the firm,” said Bitterman. “Atlas has a deep commitment to transforming medicine through groundbreaking science and a rich history of partnering with entrepreneurs at the earliest stages of company inception. I’m looking forward to contributing as the team builds the next generation of great biotech companies.”

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Kevin is an exceptional venture investor who brings proven company creation skills and deep scientific expertise to Atlas,” added David Grayzel, an Atlas partner. “We have known Kevin for years in the Boston biotech ecosystem and are delighted to welcome him to the team.”

Atlas has had a busy year, helping with a series of funding rounds for biotechs, and late last year, in a first for the life science venture capital world, teamed up with Third Rock in a $48.5 million Series A to create and launch Magenta Therapeutics—a new biotech that aims to reset and refresh the immune system.

Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

The FDA approved a new, tiny pacemaker from Medtronic that does not require the wiring of separate electrodes between the implant and the heart.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.